- Earned a $68M milestone payment from Kite for iMMagine-1 enrollment --
-- Submitted an abstract for the iMMagine-1 study at the 66th ASH Annual Meeting --
-- The global Phase 3 trial, iMMagine-3, has been initiated by Kite --
-- U.S. FDA clears anito-cel IND application for myasthenia gravis, an autoimmune disease -
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.